BR112017019343A2 - uso de composições contendo peptídeo inibidor de mk2 para tratamento de câncer de pulmão de células não pequenas com as mesmas - Google Patents

uso de composições contendo peptídeo inibidor de mk2 para tratamento de câncer de pulmão de células não pequenas com as mesmas

Info

Publication number
BR112017019343A2
BR112017019343A2 BR112017019343A BR112017019343A BR112017019343A2 BR 112017019343 A2 BR112017019343 A2 BR 112017019343A2 BR 112017019343 A BR112017019343 A BR 112017019343A BR 112017019343 A BR112017019343 A BR 112017019343A BR 112017019343 A2 BR112017019343 A2 BR 112017019343A2
Authority
BR
Brazil
Prior art keywords
tumor
lung cancer
small cell
reduce
cell lung
Prior art date
Application number
BR112017019343A
Other languages
English (en)
Portuguese (pt)
Inventor
Luber Andrew
Peterson Caryn
Brophy Colleen
Lander Cynthia
Original Assignee
Moerae Matrix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moerae Matrix Inc filed Critical Moerae Matrix Inc
Publication of BR112017019343A2 publication Critical patent/BR112017019343A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biophysics (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
BR112017019343A 2015-03-12 2016-03-10 uso de composições contendo peptídeo inibidor de mk2 para tratamento de câncer de pulmão de células não pequenas com as mesmas BR112017019343A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562132374P 2015-03-12 2015-03-12
PCT/US2016/021843 WO2016145234A2 (en) 2015-03-12 2016-03-10 Use of mk2 inhibitor peptide-containing compositions for treating non-small cell lung cancer with same

Publications (1)

Publication Number Publication Date
BR112017019343A2 true BR112017019343A2 (pt) 2018-05-02

Family

ID=56880599

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017019343A BR112017019343A2 (pt) 2015-03-12 2016-03-10 uso de composições contendo peptídeo inibidor de mk2 para tratamento de câncer de pulmão de células não pequenas com as mesmas

Country Status (13)

Country Link
US (1) US9999655B2 (enExample)
EP (1) EP3268022A4 (enExample)
JP (1) JP2018512401A (enExample)
KR (1) KR20170125090A (enExample)
CN (1) CN107921082A (enExample)
AU (1) AU2016229017A1 (enExample)
BR (1) BR112017019343A2 (enExample)
CA (1) CA2978941A1 (enExample)
HK (1) HK1249433A1 (enExample)
MX (1) MX2017011633A (enExample)
RU (1) RU2017135072A (enExample)
SG (1) SG11201707281QA (enExample)
WO (1) WO2016145234A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018102827A1 (en) * 2016-12-04 2018-06-07 Expression Pathology, Inc. Improved methods of treating lung cancer by predicting responders to cisplatin-pemetrexed combination therapy
CN110662844A (zh) * 2017-05-22 2020-01-07 内盖夫生物技术国家研究所有限公司 用于肺癌的诊断的生物标志物
US10952799B2 (en) * 2017-05-31 2021-03-23 Covidien Lp Systems and methods for navigational bronchoscopy and selective drug delivery
WO2018231722A1 (en) * 2017-06-12 2018-12-20 Moerae Matrix, Inc. Immunomodulatory effect of inhaled kinase inhibitor peptides in lung
CA3102328A1 (en) * 2018-06-12 2019-12-19 Universite De Geneve Peptidic protein kinase c inhibitors and uses thereof
WO2020102670A1 (en) * 2018-11-15 2020-05-22 Nantomics, Llc Classification based on characterization analysis methods and systems
EP4004548B1 (en) 2019-07-29 2026-01-14 Yeda Research and Development Co. Ltd Methods of treating and diagnosing lung cancer
CN113261532A (zh) * 2020-02-17 2021-08-17 中山大学 一种肺癌动物模型的构建方法
WO2021178449A1 (en) * 2020-03-02 2021-09-10 Washington University Compositions and methods for the treatment of pancreatic cancer
CA3197627A1 (en) * 2020-11-18 2022-05-27 Kimberly SHEPARD Inhalable dry powder formulations comprising angiogenesis inhibitors
EP4464694A4 (en) 2022-01-14 2026-04-01 Shanghai Hansoh Biomedical Co Ltd POLYCYCLIC DERIVATIVE CONTAINING PYRIDINE, ITS PREPARATION PROCESS AND ITS USE
US12668598B2 (en) 2022-10-27 2026-06-30 Bristol-Myers Squibb Company MK2 inhibitors and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1521000A (en) 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4227522A (en) 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
US4192309A (en) 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
DK172541B1 (da) 1982-10-08 1998-12-07 Glaxo Group Ltd Apparat til administrering af medikamenter til patienter og en medikamentpakning til brug i apparatet
AU591152B2 (en) 1985-07-30 1989-11-30 Glaxo Group Limited Devices for administering medicaments to patients
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5352461A (en) 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
AU4115693A (en) 1992-04-24 1993-11-29 Sri International In vivo homologous sequence targeting in eukaryotic cells
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
DK0733059T3 (da) 1993-12-09 2000-10-16 Univ Jefferson Forbindelser og fremgangsmåder til site-rettede mutationer i eukaryote celler
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
DK1165050T3 (da) 1999-04-05 2006-05-01 Mannkind Corp Fremgangsmåde til dannelse af fint pulver
ES2395096T3 (es) 1999-06-29 2013-02-08 Mannkind Corporation Purificación y estabilización de agentes farmacéuticos a base de péptidos y proteínas
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US20060039985A1 (en) 2004-04-27 2006-02-23 Bennett David B Methotrexate compositions
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
HUE025151T2 (en) 2004-08-23 2016-01-28 Mannkind Corp Diceto-piperazine salts for drug delivery
BRPI0514410A (pt) 2004-08-23 2008-06-10 Mannkind Corp fornecimento pulmonar de inibidores de fosfodiesterase do tipo 5
MX373000B (es) 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
CN104383546B (zh) 2006-02-22 2021-03-02 曼金德公司 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法
ES2594281T3 (es) 2007-01-10 2016-12-19 Purdue Research Foundation Inhibidores polipeptídicos de HSP27 quinasa y usos de los mismos
DK2185698T3 (en) * 2007-08-07 2015-07-27 Purdue Research Foundation Kinase Inhibitors and Uses thereof
CN102256613B (zh) 2008-10-20 2014-09-10 莫伊莱麦屈克斯公司 用于治疗或者预防粘连的多肽
US9327008B2 (en) 2008-12-10 2016-05-03 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
US9890195B2 (en) 2009-07-27 2018-02-13 Purdue Research Foundation MK2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
EP2575855A4 (en) 2010-05-24 2014-03-12 Moerae Matrix Inc METHOD FOR TREATING OR PREVENTING VASCULAR GRAFT BREAKAGE
US10105356B2 (en) * 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
CN108014340A (zh) * 2011-04-12 2018-05-11 莫伊莱麦屈克斯公司 用于预防或治疗以成纤维细胞异常增殖及细胞外基质沉积为特征的疾病的组合物和方法
US9890200B2 (en) * 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
EP3467124A1 (en) * 2012-06-06 2019-04-10 Fundació Institut de Recerca Biomèdica IRB (Barcelona) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
US20140072613A1 (en) 2012-09-10 2014-03-13 Cynthia Lander Compositions and Methods for Treating Cutaneous Scarring

Also Published As

Publication number Publication date
KR20170125090A (ko) 2017-11-13
SG11201707281QA (en) 2017-10-30
HK1249433A1 (zh) 2018-11-02
AU2016229017A1 (en) 2017-09-28
CN107921082A (zh) 2018-04-17
WO2016145234A2 (en) 2016-09-15
EP3268022A4 (en) 2018-11-21
US9999655B2 (en) 2018-06-19
RU2017135072A (ru) 2019-04-10
US20160263187A1 (en) 2016-09-15
JP2018512401A (ja) 2018-05-17
RU2017135072A3 (enExample) 2019-09-30
CA2978941A1 (en) 2016-09-15
EP3268022A2 (en) 2018-01-17
MX2017011633A (es) 2017-11-02
WO2016145234A3 (en) 2016-11-03

Similar Documents

Publication Publication Date Title
MX2017011633A (es) Uso de composiciones que contienen peptido inhibidor de mk2 para tratar cancer de pulmon de celulas no pequeñas con las mismas.
BR112022004248A2 (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para inibir a atividade de prmt5 em uma célula, e, método para o tratamento de câncer
BR112014021102A2 (pt) Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
BR112022009631A2 (pt) Combinações de inibidores de dgk e antagonistas do ponto de checagem
BR112019024674A2 (pt) Inibidores covalentes da kras
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
BR112012018951C8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
BR112012018947B1 (pt) anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica
BR112016029041A8 (pt) uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico
BR112016014481A2 (pt) tratamento de câncer utilizando combinações de inibidores de erk e raf
BR112017021869A2 (pt) compostos quinazolina substituídos e métodos de uso dos mesmos
MX2017015938A (es) Inhibidores de ezh2 para el tratar linfomas.
BR112016024379A2 (pt) variantes ldlr e seu uso em composições para reduzir os níveis de colesterol
BR112013011184A2 (pt) composições e métodos para tratamento de mielofibrose
BR112015027288A8 (pt) uso de uma dose de imunossupressor, composição de nanocarreadores sintéticos tolerogênicos e kit
BR112015026247A8 (pt) composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112014031088A2 (pt) métodos para o tratamento de câncer pancreático usando terapias de combinação que compreendem irinotecano lipossomal
BR112019017393A8 (pt) Composição farmacêutica de evolocumab e seu uso, kit, método para preparar polipeptídeo de ligação a pcsk9 e método para formular polipeptídeo terapêutico
BR112017013453A2 (pt) novo peptídeo inibidor de pi3ky para o tratamento de doenças do sistema respiratório
BR112015022650A2 (pt) inibidores de cinase induzível por sal macrocíclico
PH12016502353A1 (en) Pharmaceutical composition
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
TW201613577A (en) Pharmaceutical combinations

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]